8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2021

NEMAURA MEDICAL INC.

(Exact name of registrant as specified in its charter)

Nevada	001-38355	46-5027260
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

57 West 57th Street Manhattan, NY	10019
(Address of principal executive offices)	(Zip Code)
Registrant’s telephone number, including area code:	(646) 416-8000
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	NMRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. [_]

Item 7.01. Regulation FD Disclosure.

Beginning on March 9, 2021, management of Nemaura Medical Inc. (the “Company”) will deliver the investor presentation attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information included in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Current Report on Form 8-K, including on Exhibit 99.1 hereto, that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, or achievements to differ materially from those expressed or implied. Any forward-looking statement speaks only as of the date made. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

The words "believe," "anticipate," "design," "estimate," "plan," "predict," "seek," "expect," "intend," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the Company’s actual results to vary materially from those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the Company believes are appropriate in the circumstances. Factors which could cause actual results to differ from expectations, many of which are beyond the Company’s control, include, but are not limited to, obtaining regulatory approval for our sugarBEAT device, conducting successful clinical trials, executing agreements required to successfully advance the Company's objectives; retaining the management and scientific team to advance the product; overcoming adverse changes in market conditions and the regulatory environment; obtaining and enforcing intellectual property rights; obtaining adequate financing in the future through product licensing, public or private equity or debt financing or otherwise; dealing with general business conditions and competition; and other factors referenced in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, as the same may be updated from time to time. Except as required by law, we do not assume any obligation to update any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Presentation of the registrant dated March 9-10, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 5, 2021	NEMAURA MEDICAL INC.
	By:	/s/ Dewan F. H. Chowdhury
	Name: Title:	Dewan F. H. Chowdhury Chief Executive Officer

EX-99.1

Exhibit 99.1

Corporate Presentation H.C.WAINWRIGHT & CO Global Life Sciences Conference Dr Faz Chowdhury, CEO M arch 9 - 10, 2021

Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. • These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Annual Report on Form 10 - K filed with the Commission o n 29 June 2020, as the same may be updated from time to time. • Nemaura disclaims any obligation to update information contained in these forward - looking statements whether as a result of new information, future events, or otherwise. 2 www.nemauramedical.com

Obesity and Diabetes: TWO of the major drivers of the chronic disease Epidemic The added cost of managing a Type 2 diabetic person is >$6000/year. This can be avoided by preventing or reversing Type 2 Diabetes 3 Pre - Diabetics >80 million Type 2 >25 million

Key Targets 1. Prevent diabetes in >80 million people with pre - diabetes in the USA 1. Reverse Diabetes in >25 million persons in the USA 4

Our Solution A World first daily wear Continuous glucose monitor* Applicable for Pre - diabetes (diabetes prevention), Type 1 (glucose trending) and Type 2 Diabetes (glucose trending and diabetes reversal) Total addressable market exceeding $ 150 Billion 1,2,3 CE approved Class 2b Medical device – adjunct to finger - prick test BEAT diabetes program launched in the USA in December 2020 *Nemaura’s sensor is non - invasive and can be worn for a few hours each day instead of competing sensors that are worn for between 10 and 14 days consecutively. 1. https ://drug - dev.com/global - type - 2 - diabetes - market - set - to - almost - double - to - 58 - 7 - billion / 2. https://www.prnewswire.com/news - releases/global - digital - diabetes - market - outlook - to - 2026 - a - 16 - billion - industry - opportunity - 300980794. html 3. https://www.absolutemarketsinsights.com/reports/Global - Noninsulin - Therapies - for - Diabetes - Market - 2019 - 2027 - 259 5

Why we are different A World first daily wear Continuous glucose monitor – currently no other sensor technology like it (to best of our knowledge)* Highly competitive pricing allowing broader adoption to address unmet clinical needs Allows us to target the Medical market and consumer market with a device that is fit for both markets Excellent feedback thus far from UK based sugarBEAT® users (via UK licensee) *Nemaura’s sensor is non - invasive and can be worn for a few hours each day instead of competing sensors that are worn for between 10 and 14 days consecutively. 6

Core Technology

Benefits over HbA1c

11 FULL PROGRAM LAUNCHED DECEMBER 2020 IN USA 3 CORE COMPONENTS 1. Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence. Sustained long term weight loss achieved without loss of muscle mass 2. proBEAT Ρ glucose profiling – using world’s first daily - wearable glucose sensor, developed in - house 3. Coaching: digital 24/7 using app, and specialist 1 to 1 coaching

Intermittent Glucose Profiling: B enefits 12 7 - point glucose profiles every 4 weeks. Patients received guidance for diet and exercise adjustments based on SMBG. Outcome: Significant reductions in HbA1c, weight, BMI, systolic BP, diastolic BP, and LDL Cholesterol Kempf et. al., Diabetes Technol Ther (2010 )

13 Glucose trend and diet , exercise , and other parameters used to determine individual metabolic health . Combine with education and guidance

14 KEY MILESTONES FOR 2021 1. Adoption of BEATdiabetes program by several large corporations/employers and Insurers in the USA (initially) 2. Launch of consumer device and program addressing Metabolic health and weight loss through glucose control 3. Launch sugarBEAT real time non - invasive continuous glucose monitor in a number of territories outside the USA, and in the USA on PMA approval.

SUMMARY 1. Total addressable market >$150 Billion 2. World’s first daily wearable sensor with unparalleled economics 3. Targeting prevention and/or reversal of Type 2 diabetes with significant long term savings 4. Glucose profiling a few days a month provides a powerful cost - effective tool to facilitate management of Type 2 diabetes. 5. Combining with digital intervention/guidance/coaching, the product can be easily scaled and deployed widely to cater for the approx. 30 million people with Type 2 in the US. 6. Targeting payers such as Corporations and Insurers 7. Outstanding and growing management team 8. Revenue generating from 2021 with first mover and cost advantage 9. Strong balance sheet: over $33m on balance sheet at end of last reported quarter 10. Low quarterly cash burn, <$1.5m/quarter historically 15